Neurological Phenotype in Waardenburg Syndrome Type 4 Correlates with Novel SOX10 Truncating Mutations and Expression in Developing Brain  by Touraine, Renaud L. et al.
Am. J. Hum. Genet. 66:1496–1503, 2000
1496
Neurological Phenotype in Waardenburg Syndrome Type 4
Correlates with Novel SOX10 Truncating Mutations
and Expression in Developing Brain
Renaud L. Touraine,1,* Tania Attie´-Bitach,1,* Eric Manceau,2 Eckhard Korsch,3 Pierre Sarda,5
Ve´ronique Pingault,6 Fe´re´chte´ Encha-Razavi,1 Anna Pelet,1 Joelle Auge´,1
Annie Nivelon-Chevallier,2 Alexander Mathias Holschneider,3 Marc Munnes,4 Walter Doerfler,4
Michel Goossens,5 Arnold Munnich,1 Michel Vekemans,1 and Stanislas Lyonnet1
1De´partement de Ge´ne´tique et Unite´ de Recherches sur les Handicaps Ge´ne´tiques de l’Enfant, Hoˆpital Necker-Enfants Malades, Paris;
2Centre de Ge´ne´tique, Hoˆpital d’Enfants, Dijon, France; 3Kinderkrankenhaus, Kliniken der Stadt Ko¨ln, and 4Institut fu¨r Genetik, Universita¨t zu
Ko¨ln, Cologne, Germany; 5Unite´ de Ge´ne´tique Me´dicale et Foetopathologie, Hoˆpital Arnaud de Villeneuve, Montpellier, France; and
6Ge´ne´tique Mole´culaire et Physiopathologie, Hoˆpital Henri Mondor, Cre´teil, France
Waardenburg syndrome type 4 (WS4), also called Shah-Waardenburg syndrome, is a rare neurocristopathy that
results from the absence of melanocytes and intrinsic ganglion cells of the terminal hindgut. WS4 is inherited as
an autosomal recessive trait attributable to EDN3 or EDNRB mutations. It is inherited as an autosomal dominant
condition when SOX10 mutations are involved. We report on three unrelated WS4 patients with growth retardation
and an as-yet-unreported neurological phenotype with impairment of both the central and autonomous nervous
systems and occasionally neonatal hypotonia and arthrogryposis. Each of the three patients was heterozygous for
a SOX10 truncating mutation (Y313X in two patients and S351X in one patient). The extended spectrum of the
WS4 phenotype is relevant to the brain expression of SOX10 during human embryonic and fetal development.
Indeed, the expression of SOX10 in human embryo was not restricted to neural-crest–derived cells but also involved
fetal brain cells, most likely of glial origin. These data emphasize the important role of SOX10 in early development
of both neural-crest–derived tissues, namely melanocytes, autonomic and enteric nervous systems, and glial cells
of the central nervous system.
Introduction
Waardenburg syndrome (WS [MIM 193500, MIM
193510, MIM 600193, and MIM 148820]) is a rare
disorder (1/50,000 live births) characterized by sen-
sorineural hearing loss and pigment anomalies. On
the other hand, Hirschsprung disease (HSCR [MIM
142623]) is a common malformation (1/5,000 live
births) defined by the absence of parasympathetic gan-
glion cells in the terminal hindgut. HSCR and WS are
regarded as neurocristopathies, since both disorders re-
sult from an abnormal migration of neural-crest–derived
cells. Interestingly, each of the three animal models of
HSCR, namely the piebald lethal (sl), lethal spotting (ls),
and dominant megacolon (Dom) mutants, exhibit some
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features reminiscent of WS, such as hypomelanotic
spots. In humans, the WS-HSCR association (WS type
4 [WS4], also known as Shah-Waardenburg syndrome;
MIM 277580) is a very rare and heterogeneous condi-
tion that follows either an autosomal recessive or an
autosomal dominant pattern of inheritance (McKusick
1973; Branski et al. 1979; Omenn and McKusick 1979;
Shah et al. 1981). Both the mouse mutants and the hu-
man WS4 phenotype have been ascribed to mutations
of the endothelin-signaling pathway—namely, the en-
dothelin B receptor, EDNRB, and the endothelin 3 gene,
EDN3 (Attie´ et al. 1995; Edery et al. 1996)—or of the
SOX10 gene, which encodes a transcription factor (Pin-
gault et al. 1998). Hitherto, no additional features have
been described among WS4 patients. Here, we report
on three unrelated WS4 patients who presented with an
as-yet-unreported progressive neurological involvement
of both central and peripheral nervous systems. We show
that the three patients carried a truncating SOX10 mu-
tation. Accordingly, analysis of data generated from in
situ hybridization experiments indicated that SOX10 is
expressed early in the fetal brain, likely in glial cells.
Thus, our study gives support to a possible neurological
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Table 1
WS4 Phenotype for Members of the Three Families Studied
FEATURE
PRESENCE OF FEATURE IN
Family 1 Family 2 Family 3a
Colonic aganglionosis Total Short segment Total
Iris heterochromia 1 1 2
Deafness 1 1 1
Mental retardation Severe Very mild ND
Cerebellar ataxia 1 1 ND
Nystagmus 1 1 ND
Spasticity 1 1 1
Alacrima 1 1 ND
Asialia 2 1 ND
Reduced sweating 2 1 ND
Seizures 2 1 2
Growth failure 1 1 ND
Hypogonadism 1 2 ND
NOTE.—A plus sign (1) indicates presence, and a minus sign
(2) indicates absence.
a ND = not determined.
involvement in WS4 and to the role of SOX10 in de-




Histopathologic inclusion criteria for HSCR were gan-
glia that were absent, along with increased acetylcho-
linesterase histochemical staining in nerve fibers on suc-
tion biopsies of the rectal mucosa. For WS, we used the
diagnostic criteria of Read and Newton (1997), and
WS4 was diagnosed when at least one member of the
proband’s family had features of both HSCR and WS.
Informed consent was obtained for all the patients in
the study.
Among a total of 12 unrelated WS4 patients recruited
by the Genetic Center, Necker Hospital, Pais, three pre-
sented with additional neurological symptoms. Each of
them originated from white families living in Germany
(family 1) and France (families 2 and 3). Their standard
blood-lymphocyte karyotypes were within normal ref-
erence ranges.
Patient 1 had early delayed developmental milestones,
nystagmus, myopia, reduced tear production, hypo-
tonia, and growth deficiency (height, 104 cm; weight,
15.8 kg; and head circumference, 52 cm at age 12 years).
In addition to extensive intestinal aganglionosis, deaf-
ness, iris heterochromia, and hypomelanic skin patches
consistent with WS4, patient 1 developed cerebellar
ataxia, spasticity, and severe mental retardation (table
1). Several computed-tomography scans revealed only a
slight cerebral atrophy. Pupillary light reflexes, optical
fundus, sensitivity to pain and temperature, sense of
smell, sweating, and salivation were normal. Echocar-
diography and 24-h electrocardiogram were unremark-
able, but heart-rate variation parameters indicated an
autonomic dysregulation. Similarly, there was almost no
local reaction to the histamine test (flare !2 mm). Fur-
thermore, he developed hepatosplenomegaly and portal
hypertension of unknown origin. Three other boys who
were members of his family had died during the first
week of life; they had intestinal obstruction, and it was
likely that they had WS, since the third child had patchy
depigmentation of the scalp and white hair (fig. 1). Nei-
ther the mother nor any other family member had any
signs of WS or HSCR.
In family 2, the proband was initially diagnosed with
short-segment aganglionosis; he then presented with
myoclonia at age 2 wk. Computed-tomography scans of
his brain revealed no abnormalities. He responded well
to phenobarbitone, but, later, he developed nystagmus,
head bobbing, and paroxysmal movements of the upper
limbs without accompanying abnormalities (as assessed
by electroencephalogram or brain magnetic-resonance
imaging). On the basis of a later occurrence of torticollis
and the benign course of the nystagmus, head bobbing,
and paroxysmal movement, a putative diagnosis of spas-
mus nutans was made, despite the early onset of symp-
toms and despite the presence of abnormal movements
of the limbs. Later, antiepileptic drugs were withdrawn
without any recurrence of seizures. Ataxia, spasticity,
and reduced productions of tears, saliva, and sweat de-
veloped progressively. Growth failure occurred at age 8
years, and, at the time of the study, he was on the 22
SD curve. He had neither hypomelanic lesions nor he-
patosplenomegaly. Neither his parents nor any other
family member had any signs of WS or HSCR.
The proband of family 3 was the first child of young
parents. There was no history of either WS- or HSCR-
affected members of the proband’s family. A reduction
of fetal movement was noted during the last month of
pregnancy. Height, weight, and head circumference at
birth were 50 cm, 2,980 g, and 35.5 cm, respectively.
Severe neonatal distress required immediate resuscita-
tion and admission to an intensive care unit. He pre-
sented with coma, arthrogryposis, meconial ileus, and a
white forelock, but he did not have heterochromia irides.
Analysis of intestinal biopsies led to the diagnosis of
severe aganglionosis extending to the jejunum. Optical
fundus were normal. Neither auditory brain stem–
evoked responses nor electromyographic reactivity could
be found. Electroencephalogram was abnormal, show-
ing immaturity and discontinuity of the tracing, but par-
oxysmal discharges were not present. Analysis of muscle
biopsy showed no specific lesions. He died on day 11
of life.
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Figure 1 Y313X and S251X SOX10 mutations. A, DNA sequence of SOX10 exon 5 showing the normal sequence (N) and the Y313X
heterozygous mutation (arrow) in the proband (family 1). B, DNA sequence of SOX10 exon 5 showing the normal sequence (N) and the S251X
heterozygous mutation in the proband (family 3). C, Family 1 with pedigree and PCR-amplified exon 5 of the SOX10 gene, digested with DdeI:
normal allele (1) = 201 1 66 bp (132-bp fragment nonvisible), mutated allele (m) = 256 bp (132-bp fragment nonvisible).
DNA Analysis
Mutation screening of SOX10 coding sequence was
performed by SSCP as previously described, except gel
electrophoreses were performed in two different con-
ditions: at room temperature and in a cold room (Pin-
gault et al. 1998). In brief, PCR reactions were per-
formed on 200 ng of DNA with Taq DNA polymerase
(BRL). PCR products were heated for 10 min at 957C
in an equal volume of denaturing loading buffer and
loaded onto an mutation-detection enhancement gel
(FMC). The gels were then dried and autoradiographed
for 24–72 h. PCR products that showed an abnormal
SSCP pattern were directly sequenced on both strands
by the fluorometric method (DyeDeoxy or BigDye Ter-
minator Cycle sequencing kit; Applied Biosystems).
When possible, mutations were confirmed by restriction-
enzyme digestion on PCR amplification products.
In Situ Hybridization
Human embryos were collected from legally termi-
nated pregnancies, in agreement with French law and
the recommendations of the French Ethics Committee.
Embryos were staged under a microscope according to
the Carnegie classification criteria. Brain and organs of
a 20-wk fetus were also studied. Tissues were fixed with
4% paraformaldehyde, embedded in paraffin blocks,
and sectioned at 5 mm. PCR amplification of human
genomic DNA with SOX10 exon 5 primers 5/2F and
5/2R (GGTAATGTCCAACATGGAGACC and GTA-
GGCGATCTGTGAGGTGG, respectively) were cloned
into pCR-Script Amp SK(1) (Stratagene). Sense and
antisense riboprobes were generated by either T7 or T3
RNA polymerase in the presence of a35S-uridine
5′(a-thio)triphosphate (1,200 Ci/mmol; NEN). Labeled
probes were purified on Sephadex G50 columns. Hy-
bridization and posthybridization washes were carried
out according to standard protocols (Wilkinson 1992).
Slides were dehydrated, exposed to Biomax MR X-ray
films (Amersham) for 3 d, dipped in Kodak NTB2 emul-
sion for 3 wk at 147C, and then developed and coun-
terstained with toluidine blue, coverslipped with Eukitt,
and analyzed with dark- and bright-field illumination.
No hybridization signal was detected with the a35S-la-
beled sense probes, which confirmed that the in situ hy-
bridization patterns of the a35S-labeled antisense probes
were specific. No cross-hybridization with SOX9 m-
RNAs was observed (data not shown).
Results
DNA Analysis
Abnormal SSCP patterns were detected in the SOX10
gene in all three WS4 patients studied. In each patient,
a heterozygous mutation was located in SOX10 exon
5, either at nucleotide 939 (TACrTAA) or at nucleotide
752 (TCGrTAG), which predicted nonsense mutations
at codon 313 (Y313X) and 251 (S251X), respectively
(fig. 1A, 1B). The Y313X mutation abolished a DdeI
restriction site and was found in families 1 (fig. 1C) and
2. In family 1, the mutation was inherited from the un-
affected mother (fig. 1C), whereas, in family 2, the mu-
tation was not inherited from the mother and the father
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Table 2
SOX10 Expression in Early Human Embryogenesis
VARIABLE
EXPRESSION AT CARNEGIE STAGEa
13 14 16 17
Central nervous system 2 2 2 2
Peripheral nervous system:
Enteric nervous system Migrating cells 1 11 111
Tracheal nervous system Migrating cells 1 11 111
Ganglia:
Cranial 1 1 11 111
Dorsal root 1 1 11 111
Sympathetic 1 1 11 111
Peripheric nerves 2 2 11 111
Ectomesenchyme 2 1 11 Meckel 11; nasal
cartilage 111
Otic vesicle 1 1 11 Internal ear 111
Testis 2 2 2 111
Pancreas 2 2 2 111
Lingual glands 2 2 2 111
NOTE.—A plus sign (1) indicates presence, and a minus sign (2) indicates absence
of the indicated expression. 1, 11, and 111 = relative levels of expression.
a Carnegie stage corresponds to the following ages: Carnegie 13, 28–31 d; Carnegie
14, 32 d; Carnegie 16, 37–40 d; and Carnegie 17, 41–43 d.
was not available for study. The S251X SOX10 trun-
cating mutation arose de novo in a boy (family 3) with
hypotonia and arthrogryposis who died soon after birth.
No other variation in the SOX10 gene was found, and
no abnormal SSCP pattern could be detected in the RET
gene-coding sequence in the patients studied. The pe-
culiar neurological phenotype, together with the similar
localization of SOX10 mutations in these WS4 patients,
prompted us to look for SOX10 expression during early
human brain development.
SOX10 Expression in Developing Humans
Table 2 summarizes the expression pattern of SOX10
in five human embryos in Carnegie stages 13–17 (days
28–43). At Carnegie 13, SOX10 was strongly expressed
in dorsal-root ganglia, otic vesicle (fig. 2A, 2B), and cells
migrating around the aorta, in branchial arches, and
toward the gut and tracheal bud (data not shown). At
Carnegie 16, signal intensity increased in each of these
areas (fig. 2C, 2D). In addition, nerve fibers originating
from the anterior horn of the spinal cord expressed
SOX10 over their whole length up to the target tissues,
whereas the anterior horn was negative (fig. 2D). At
Carnegie 17, SOX10 expression increased in ganglia and
extended to cranial ectomesenchyme, inner ear (semi-
circular canals, utricle, and saccula), and some regions
of the maxilla, mandible, and tongue, consistent with
the labeling of innervating fibers (fig. 2F). In the gut,
expression was restricted to the outer muscular layer,
where the enteric plexuses are located. Testis and de-
veloping pancreas were also SOX10 positive (data not
shown). No SOX10 transcripts could be detected in the
central nervous system at any of the embryonic stages
studied.
No SOX10 expression in the cerebral cortex and brain
nuclei was observed consistently in a 20-wk fetal brain.
However, a diffuse but variable expression was seen in
the other areas of the brain. High-power magnification
showed that the signals were located in some strongly
positive nonneuronal cells scattered in several glial-rich
areas, namely pons (fig. 3A, 3B), cerebellum (fig. 3H),
tectum of peduncle (fig. 3E), internal capsule (fig. 3D),
and hippocampal formations (fig. 3F, 3G), consistent
with SOX10 expression in glial cells. Fetal expression
of SOX10 was also observed in the enteric and tracheal
nervous systems, in pancreas acini, and in adrenal me-
dulla (data not shown). Finally, no expression was de-
tected in heart, kidney, thymus, spleen, or muscle. These
results were in agreement with previous data (Bondur-
and et al. 1998).
Discussion
WS4 is a rare neurocristopathy that results in the absence
of melanocytes and inner ear cells (WS) and parasym-
pathetic enteric neurons of the terminal hindgut (HSCR;
McKusick 1973; Branski et al. 1979; Omenn and
McKusick 1979; Shah et al. 1981). WS4 is transmitted
either as a recessive or a dominant autosomal trait, de-
pending on whether the endothelin-signaling pathway
(Puffenberger et al. 1994; Attie´ et al. 1995; Edery et al.
1996; Bidaud et al. 1997) or SOX10 mutations (Pingault
et al. 1998) are involved, respectively. Yet several WS4
cases are not related to EDNRB, EDN3, or SOX10
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Figure 2 SOX10 expression in transverse sections of a Carnegie 13 human embryo, under dark-field illumination. A, Cranial nerve ganglia
(V, VII/VIII, and IX/X) and otic vesicle (OV). Also shown, neural tube (NT). B, Dorsal root ganglia (DRG). SOX10 expression in transverse
sections through a Carnegie 16 human embryo under dark-field illumination. Also shown, heart (H) C, Cranial nerve ganglia V and ectome-
senchyme (EM). Also shown, nasal pits (NP), optic vesicle (Opv), rhombencephalon (Rh), and Rathke pouch (RP). D, Dorsal root (DR), dorsal
root ganglia (DRG), spinal nerve (SN), and ventral root (VR) merging from the anterior horn (AH). Serial parasagittal sections through a
Carnegie 17 human embryo, either hematoxylin and eosin–stained (E) or hybridized with SOX10 riboprobe and examined under dark-field
illumination (F), which shows SOX10 expression in the cranial ganglia (V, VII/VIII, and IX/X), olfactory bulb (OlfB), cranial ectomesenchyme
(i.e., Meckel cartilage [MC] and nasal cartilage [NC]), nerves in intercostal spaces, nerve fibers (N) in maxilla (Max), mandible (Man), and
tongue (To), internal ear (semicircular canals [SCC], utricle, and saccula [U/S]), and the ultimobranchial body (UBB).
mutations. Among a total of 12 probands who presented
with WS4 features (deafness, pigment anomalies, and
HSCR), we have studied members of three families with
a progressive neurological phenotype. There have been
very few reports of WS patients with neurological in-
volvement, including mental retardation with seizures or
dystonia, muscular stiffness, and peripheral neuropathy,
but none had HSCR (Kawabata et al. 1987; Cantani et
al. 1989). Conversely, only two siblings have been re-
ported with extensive digestive dysganglionosis, ataxia,
peripheral neuropathy, and dysautonomic features but
no feature of WS (Schuffler et al. 1978). Therefore, when
we started this study, the patients presented an as-yet-
unreported association. Although several hypotheses re-
garding the additional neurological symptoms could
have been raised (such as a contiguous gene syndrome),
we ascribed the disorder to truncating SOX10 mutations
in individuals in each of the three families studied. This
hypothesis was further supported by two articles that
describe WS4 patients with SOX10 mutation and neu-
rological features, published while this article was in
preparation. Two siblings who harbored phenotypes
very similar to those of the patients we studied, including
nystagmus and ataxic cerebral palsy (although only one
of them had HSCR), were found to be heterozygous for
the Q377X SOX10 mutation (Southard-Smith et al.
1999). Furthermore, Inoue et al. (1999) described a pa-
tient with WS4, demyelinating neuropathy, and severe
leukodystrophy. This patient harbored a heterozygous
1400del12 SOX10 mutation that modified the 467 stop
codon and extended the SOX10 protein with 82 amino
acids.
SOX10 is a member of the SOX family of transcrip-
tion factors and local organizers of chromatin structure
(Pevny and Lovell-Badge 1997). Binding of SOX-pro-
tein high-mobility group (HMG) domain to the specific
DNA sequence motif A/T A/T CAA A/T G results in
DNA bending. There is no evidence for target specificity,
but rather there is evidence for tissue- and stage-specific
expression, which delimits a specific role for each of the
SOX family members. We speculate that the SOX10
Y313X and S251X nonsense mutations are responsible
for both WS4 and the additional neurological pheno-
type. Indeed, our data about SOX10 expression support
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Figure 3 SOX10 expression in fetal brain. Transverse sections of the brain of a 20-wk fetus. A, F, H, hematoxylin and eosin staining.
B, C, D, E, G, I, SOX10 in situ hybridization under dark-field illumination. C is a higher-magnification view of B (boxed area). A diffuse
SOX10 expression is seen in many areas of the brain, located in some strongly positive cells scattered in the white matter, respecting the
pyramidal tracts (A, B). Signal is more intense in pons (A–C); internal capsule (D); peduncle, especially in tectum (E); hippocampal formation
(F, G); and cerebellum (H, I). J, Adjacent slide to I, hybridized with the sense (control) SOX10 probe. Cranial nerves are strongly labeled as
shown for the nerve of cranial nerve ganglia VIII N (B, C). Py = pyramidal tracts.
Figure 4 Representation of SOX10 protein with the transacti-
vation domain and the HMG box, which shows the position of the
seven previously reported mutations, the mutation responsible for the
murine Dom mutant, and the two novel mutations. The mutations
associated with an additional neurological phenotype are provided
(upper part).
its important role in neural-crest and brain develop-
ment, especially since autonomous nervous system ab-
normalities are involved in the patients—namely, re-
duction in sweat, tear, and saliva production. Both the
distribution and the morphology of the strongly positive
cells scattered in fetal-brain white matter support the
expression of SOX10 in glial cells—namely, oligoden-
drocytes, astrocytes, or immature glial cells—rather
than neurons (fig. 3). Interestingly, in rodents, Sox10 is
expressed in glial precursors and then in oligodendro-
cytes (Kuhlbrodt et al. 1998a). Although it is premature
to establish the involvement of a specific subtype of glial
cells in the central nervous system symptoms observed
in the patients we studied, we can speculate on astrocyte
impairment, according to recent data, which shows that
cerebellar ataxia developed in mice after postnatal de-
struction of astrocytes (Delaney et al. 1996), whereas
oligodendrocyte dysfunction would instead result in
leukodystrophy.
The spectrum of SOX10 mutations reported to date
supports the hypothesis that haploinsufficiency is the
mechanism for dominance in WS4. Indeed, when we
used a functional assay for SOX10 transcriptional ac-
tivity, two nonsense and one frameshift SOX10 muta-
tions resulted in loss of function, as shown in vitro (fig.
4; Kuhlbrodt et al. 1998b; Pingault et al. 1998). Since
the patients with WS4 reported here also carry hetero-
zygous mutations that truncate the last 216 and 154
amino acids residues of SOX10 for the S251X and
Y313X mutations, respectively, there is no clear expla-
nation for the phenotypic differences. However, it is
worth noting that, so far, only the S251X and Y313X
mutations are located between the HMG box and the
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transactivation domain, in a SOX10 region of unknown
function (fig. 4). In addition, patients with SOX10 mu-
tations that result in either more proximal or more distal
truncations, such as E189X, Y207X, or 1076delGA (in
order, from more proximal to more distal), did not show
any neurological symptoms (Pingault et al. 1998; Sou-
thard-Smith et al. 1999). The patients with nystagmus
and ataxic cerebral palsy, briefly described by Southard-
Smith et al. (1999), had a truncating mutation, Q377X,
that removed only the transactivation domain. Con-
versely, the patient described by Inoue et al. (1999) had
a mutation at the SOX10 3′ end that resulted in the
addition of 82 amino acids to the protein. Nevertheless,
a possible hypothesis for the extended clinical spectrum
in these patients would be that the S251X, Y313X,
Q377X, and 1400del12 SOX10 mutations resulted in
a dominant negative effect. Indeed, such proteins with
either an absent or a drastically modified transactivation
domain, but that retained the HMG box, might have
an enhanced DNA binding ability, blocking the prom-
otor of SOX10-responding genes, without transacti-
vation. Similar mechanisms have been demonstrated for
other mutant transcription factors such as PAX6 (Singh
et al. 1998) and MGF-Stat5 (Moriggl et al. 1996). Un-
fortunately, we failed to amplify by reverse transcrip-
tase–PCR any SOX10 mRNA, either normal or mutant,
from lymphoblasts or leukocytes from patient 2 (data
not shown). Therefore, mutant mRNA instability can-
not be excluded: such a phenomenon, which has been
reported several times in various genes, would preclude
any dominant negative effect (Maquat 1995). Addi-
tional patients with a SOX10 mutation are necessary
to confirm the preliminary correlation between the phe-
notype and the location of truncating mutation. Alter-
natively, the wide phenotypic spectrum of SOX10 mu-
tations may be explained by the effect of modifier genes,
such as those identified in oligogenic neurocristopathies
such as nonsyndromic HSCR (Puffenberger et al. 1994;
Salomon et al. 1996; Doray et al. 1998; Bolk et al.
2000), especially since the reported cases have been as-
certained through the intestinal phenotype. The absence
of HSCR in one of the two sibs with nystagmus and
ataxic cerebral palsy, ascribed to the Q377X SOX10
mutation (Southard-Smith et al. 1999), supports this
hypothesis, but this is not sufficient to exclude the other
mechanisms as far as the neurological phenotype is
concerned.
Our study also emphasizes the apparently high rate
of new mutations at the SOX10 locus. Indeed, in a total
of 11 informative WS4 families studied, 7 of 11 SOX10
mutations arose de novo in the probands (Pingault et
al. 1998; Inoue et al. 1999; Southard-Smith et al. 1999;
this report; unpublished data). This does not seem to
be related to a mutational hot spot, since most of the
SOX10 mutations are different. Along this line, there
is no clear explanation for the recurrence of the SOX10
Y313X mutation, since it does not involve a CpG di-
nucleotide. It is thus possible that the high proportion
of new mutations is due to an observation bias related
to the severity of the WS4 phenotype, since most af-
fected individuals are unlikely to reproduce. Of interest,
in family 1, the mother of the proband did not show
any symptoms, although she carried this Y313X mu-
tation. It can be attributable either to a lack of pene-
trance—which would be surprising as far as a dominant
negative effect of the mutation is postulated—or to so-
matic mosaicism. Indeed, the mutated Y313X allele in
the mother had a significantly weaker intensity than the
normal allele, compared with the pattern of her affected
son (fig. 1). Furthermore, the DNA sequence of SOX10
exon 5 in the mother was almost normal, with the mu-
tant peak barely visible on the electropherogram (data
not shown). Altogether, this favored the possibility of
mosaicism. Unfortunately, the mother refused to allow
us to further investigate her tissue samples. Mosaicism
seemed to be present also in the father of the family
described by Southard-Smith et al. (1999), as associated
with the Q377X SOX10 mutation.
This study highlights the role of SOX10 as an im-
portant factor in development of both neural-crest–
derived cells and glial cells of the central nervous system,
which supports its involvement not only in WS4 but
also in an extended progressive neurological phenotype,
including growth retardation, impairment of the auton-
omous system (asialia, alacrima, and hypohidrosis), and
central nervous system anomalies, namely neonatal hy-
potonia with arthrogryposis, ataxia, pyramidal signs,
nystagmus, seizure, and mental retardation. Thus, these
data suggest that SOX10 might be regarded as an in-
teresting candidate gene in other neurodegenerative dis-
orders, especially since the penetrance for HSCR is in-
complete in WS4.
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